ArticleNPJ genomic medicine2018
Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples.
Article in NPJ genomic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Convergent genomic and molecular features predict risk of metachronous metastasis in clear cell renal cell carcinoma.Communications medicine · 2026Article
- A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors.EMBO molecular medicine · 2025Article
- Integrated Transcriptomic Analysis Leveraging Single-Cell and Bulk RNA Sequencing Data to Uncover Pyroptosis-Related Prognostic Signatures in HCC.Journal of hepatocellular carcinoma · 2025Article
- Prognostic iron-metabolism signature robustly stratifies single-cell characteristics of hepatocellular carcinoma.Computational and structural biotechnology journal · 2024Article
- Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census.NPJ precision oncology · 2024Article
- Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma.Cancers · 2024Article
- Identification and validation of a platelet-related signature for predicting survival and drug sensitivity in multiple myeloma.Frontiers in pharmacology · 2024Article
- A glycolysis-related signature to improve the current treatment and prognostic evaluation for breast cancer.PeerJ · 2024Article
- Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.BMC cancer · 2023Article
- Activin A-Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Article
- Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Identification of a CircRNA-miRNA-mRNA Network and Integrated Analysis of Immune Infiltration in Oral Squamous Cell Carcinoma.Journal of Cancer · 2023Article
- Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma.Cancers · 2022Article
- Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.Frontiers in immunology · 2022Article
- Amino acid metabolism-based molecular classification of colon adenocarcinomaFrontiers in immunology · 2022Article
- Prognostic necroptosis-related gene signature aids immunotherapy in lung adenocarcinoma.Frontiers in genetics · 2022Article
- The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.BMC cancer · 2021Article
- Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune heterogeneity within the tumor microenvironment undoubtedly adds several layers of complexity to our understanding of drug sensitivity and patient prognosis across various cancer types. Within the tumor microenvironment, immunogenicity is a favorable clinical feature in part driven by the antitumor activity of CD8+ T cells. However, tumors often inhibit this antitumor activity by exploiting the suppressive function of regulatory T cells (Tregs), thus suppressing the adaptive immune response. Despite the seemingly intuitive immunosuppressive biology of Tregs, prognostic studies have produced contradictory results regarding the relationship between Treg enrichment and survival. We therefore analyzed RNA-seq data of Treg-enriched tumor samples to derive a pan-cancer gene signature able to help reconcile the inconsistent results of Treg studies, by better understanding the variable clinical association of Tregs across alternative tumor contexts. We show that increased expression of a 32-gene signature in Treg-enriched tumor samples (
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.